- Harvard Sciences and Technology (HST) Faculty, MD Alumnus
- Whitaker Professor in Biomedical Engineering, Massachusetts Institute of Technology
- Co-Director, Biomedical Enterprise Program, HST
- Director, NASA Center for Quantitative Physiology, Modeling and Data Analysis, HST
Richard J. Cohen received his MD degree from Harvard Medical School in 1976 and his PhD in Physics in the same year from MIT. He pursued clinical training at the Brigham and Women’s Hospital in Boston in Internal Medicine and Cardiology. Since 1979 he has been on the MIT faculty where he is currently the Whitaker Professor in Biomedical Engineering within the Institute of Medical Engineering and Science.
For 25 years he served as an Associate Physician at the Brigham and Women’s Hospital, for ten years he directed the Center for Biomedical Engineering of the Harvard-MIT Division of Health Sciences and Technology (HST), and for eight years he was Team Leader of the Cardiovascular Alterations Team of the National Space Biomedical Research Institute. For eight years Dr. Cohen co-directed the Biomedical Enterprise Program of HST and the MIT Sloan School of Management. Students in this program obtained an MBA degree and an SM degree in Health Sciences and Technology preparing them for leadership positions in the biomedical industry. Dr. Cohen has also directed his Division’s Cardiovascular Pathophysiology and Principles of Pharmacology courses taken by both MD and PhD students. He has taught a variety of courses in biophysics, bioengineering, signal processing and in biomedical enterprise. He is interested in health, medicine, quantitative analysis, modeling, and biomedical enterprise.
- PhD in Physics, Massachusetts Institute of Technology, 1976
- MD in Medicine, Harvard Medical School, 1976
- BA in Chemistry and Physics, Harvard College, 1971
- Detur Prize Recipient
- National Science Foundation Fellow
- John A. and George L. Hartford Fellow
Dr. Cohen focuses on the application of physics and engineering to solve problems in biology and medicine, particularly in developing cardiovascular diagnostic and therapeutic technologies. He has developed a noninvasive measurement of microvolt level fluctuations in electrocardiographic signals to identify individuals at risk for sudden cardiac death form heart rhythm disturbances. Cambridge Heart, Incorporated, a company that Dr. Cohen helped found, has commercialized this technology, which is called the “measurement of microvolt T-wave alternans.” The technology has been successfully tested in a wide range of international clinical trials and is being introduced into widespread clinical practice.
A full list of Dr. Cohen’s publications can be found on his website.
- HST 973 – FA 2013 – Evaluating a Biomedical Business Concept
- HST 979 – SP 2013 – Dynamics of Biomedical Technologies